Compare EXACT Sciences Corp. with Similar Stocks
Stock DNA
Pharmaceuticals & Biotechnology
USD 19,463 Million (Small Cap)
NA (Loss Making)
NA
0.00%
0.54
-4.28%
7.78
Revenue and Profits:
Net Sales:
811 Million
(Quarterly Results - Jun 2025)
Net Profit:
-1 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
127.4%
0%
127.4%
6 Months
66.06%
0%
66.06%
1 Year
138.42%
0%
138.42%
2 Years
16.46%
0%
16.46%
3 Years
148.02%
0%
148.02%
4 Years
-16.12%
0%
-16.12%
5 Years
10.25%
0%
10.25%
EXACT Sciences Corp. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
21.05%
EBIT Growth (5y)
4.82%
EBIT to Interest (avg)
-17.51
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0.66
Sales to Capital Employed (avg)
0.51
Tax Ratio
0.86%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
4.32
EV to EBIT
-62.48
EV to EBITDA
493.99
EV to Capital Employed
3.00
EV to Sales
4.22
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-4.81%
ROE (Latest)
-7.34%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
Bearish
No Signal
Bollinger Bands
Mildly Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
Mildly Bullish
No Trend
OBV
Mildly Bullish
Mildly Bullish
Shareholding Snapshot : Sep 2025
Shareholding Compare (%holding) 
Majority shareholders
Domestic Funds
Domestic Funds
Held in 128 Schemes (59.89%)
Foreign Institutions
Held by 340 Foreign Institutions (18.1%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY
Jun'25
Jun'24
Change(%)
Net Sales
811.10
699.30
15.99%
Operating Profit (PBDIT) excl Other Income
58.00
31.10
86.50%
Interest
9.80
8.40
16.67%
Exceptional Items
-4.90
2.10
-333.33%
Consolidate Net Profit
-1.20
-15.80
92.41%
Operating Profit Margin (Excl OI)
3.40%
-31.30%
3.47%
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2025 is 15.99% vs 12.41% in Jun 2024
Consolidated Net Profit
YoY Growth in quarter ended Jun 2025 is 92.41% vs 80.49% in Jun 2024
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
2,758.90
2,499.80
10.36%
Operating Profit (PBDIT) excl Other Income
23.10
-76.40
130.24%
Interest
32.60
9.10
258.24%
Exceptional Items
-846.60
7.10
-12,023.94%
Consolidate Net Profit
-1,028.90
-204.10
-404.12%
Operating Profit Margin (Excl OI)
-69.50%
-124.40%
5.49%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 10.36% vs 19.93% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is -404.12% vs 67.27% in Dec 2023
About EXACT Sciences Corp. 
EXACT Sciences Corp.
Pharmaceuticals & Biotechnology
Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer and Oncotype DX. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Cologuard test is intended for the qualitative detection of colorectal neoplasia associated DNA markers and for the presence of occult hemoglobin in human stool. It focuses on the development of additional tests for other types of cancer. It is developing a blood-based biomarker test to aid in the early detection of lung cancer in individuals with lung nodules discovered through a computerized tomography (CT) or other scan.
Company Coordinates 
Company Details
5505 ENDEAVOR LANE , MADISON WI : 53719
Registrar Details






